Cytomegalovirus infection in immunocompetent critically ill adults: literature review

Annals of Intensive Care

Volumn 6, Issue 1, 2016, Pages

  Al Omari, Awad ^a,b   Aljamaan, Fadi ^c   Alhazzani, Waleed ^d   Salih, Samer ^a   Arabi, Yaseen ^e  

^a POBox 100266   (Saudi Arabia)

^b ALFAISAL UNIVERSITY   (Saudi Arabia)

^c KING KHALID UNIVERSITY HOSPITAL   (Saudi Arabia)

^d MCMASTER UNIVERSITY   (Canada)

^e KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES   (Saudi Arabia)

Author keywords

Critical illness; Cytomegalovirus; Immunocompetent; Infection

Indexed keywords

ANTIVIRUS AGENT;

ANTIVIRAL THERAPY; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); CRITICAL ILLNESS; CRITICALLY ILL PATIENT; CYTOMEGALOVIRUS INFECTION; HISTOPATHOLOGY; HUMAN; IMMUNOASSAY; IMMUNOCOMPROMISED PATIENT; INCIDENCE; INFECTION PREVENTION; INFECTION RISK; NONHUMAN; PATHOGENESIS; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SEROLOGY; VIRUS CULTURE;

EID: 84994212732     PISSN: None     EISSN: 21105820     Source Type: Journal    
DOI: 10.1186/s13613-016-0207-8     Document Type: Review

References (60)

1. Limaye AP, Kirby KA, Rubenfeld GD, Leisenring WM, Bulger EM, Neff MJ, et al. Cytomegalovirus reactivation in critically ill immunocompetent patients. JAMA. 2008;300(4):413–22.
2. Ziemann M, Sedemund-Adib B, Reiland P, Schmucker P, Hennig H. Increased mortality in long-term intensive care patients with active cytomegalovirus infection. Crit Care Med. 2008;36(12):3145–50.
3. Sinclair J. Human cytomegalovirus: latency and reactivation in the myeloid lineage. J Clin Virol. 2008;41(3):180–5.
4. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis. 2002;34(8):1094–7.
5. Kotton CN, Kumar D, Caliendo AM, Asberg A, Chou S, Danziger-Isakov L, et al. Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation. 2013;96(4):333–60.
6. Andrews PA, Emery VC, Newstead C. Summary of the British Transplantation Society guidelines for the prevention and management of CMV disease after solid organ transplantation. Transplantation. 2011;92(11):1181–7.
7. Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J, et al. Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective. Preface. Bone Marrow Transplant. 2009;44(8):453–5.
8. Osawa R, Singh N. Cytomegalovirus infection in critically ill patients: a systematic review. Crit Care. 2009;13(3):R68.
9. Clari MA, Aguilar G, Benet I, Belda J, Gimenez E, Bravo D, et al. Evaluation of cytomegalovirus (CMV)-specific T-cell immunity for the assessment of the risk of active CMV infection in non-immunosuppressed surgical and trauma intensive care unit patients. J Med Virol. 2013;85(10):1802–10.
10. Chiche L, Forel JM, Thomas G, Farnarier C, Cognet C, Guervilly C, et al. Interferon-gamma production by natural killer cells and cytomegalovirus in critically ill patients. Crit Care Med. 2012;40(12):3162–9.
11. Venet F, Davin F, Guignant C, Larue A, Cazalis MA, Darbon R, et al. Early assessment of leukocyte alterations at diagnosis of septic shock. Shock. 2010;34(4):358–63.
12. Frantzeskaki FG, Karampi ES, Kottaridi C, Alepaki M, Routsi C, Tzanela M, et al. Cytomegalovirus reactivation in a general, nonimmunosuppressed intensive care unit population: incidence, risk factors, associations with organ dysfunction, and inflammatory biomarkers. J Crit Care. 2015;30(2):276–81.
13. Cook CH, Trgovcich J. Cytomegalovirus reactivation in critically ill immunocompetent hosts: a decade of progress and remaining challenges. Antivir Res. 2011;90(3):151–9.
14. Hummel M, Abecassis MM. A model for reactivation of CMV from latency. J Clin Virol. 2002;25(Suppl. 2):S123–36.
15. Guedes MI, Risdahl JM, Wiseman B, Molitor TW. Reactivation of porcine cytomegalovirus through allogeneic stimulation. J Clin Microbiol. 2004;42(4):1756–8.
16. Emery VC. Progress in understanding cytomegalovirus drug resistance. J Clin Virol. 2001;21(3):223–8.
17. Shuster EA, Beneke JS, Tegtmeier GE, Pearson GR, Gleaves CA, Wold AD, et al. Monoclonal antibody for rapid laboratory detection of cytomegalovirus infections: characterization and diagnostic application. Mayo Clin Proc. 1985;60(9):577–85.
18. Penfold ME, Dairaghi DJ, Duke GM, Saederup N, Mocarski ES, Kemble GW, et al. Cytomegalovirus encodes a potent alpha chemokine. Proc Natl Acad Sci USA. 1999;96(17):9839–44.
19. Roberts ET, Haan MN, Dowd JB, Aiello AE. Cytomegalovirus antibody levels, inflammation, and mortality among elderly Latinos over 9 years of follow-up. Am J Epidemiol. 2010;172(4):363–71.
20. Sullivan V, Talarico CL, Stanat SC, Davis M, Coen DM, Biron KK. A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells. Nature. 1992;359(6390):85.
21. Beersma MF, Bijlmakers MJ, Ploegh HL. Human cytomegalovirus down-regulates HLA class I expression by reducing the stability of class I H chains. J Immunol. 1993;151(9):4455–64.
22. Littler E, Stuart AD, Chee MS. Human cytomegalovirus UL97 open reading frame encodes a protein that phosphorylates the antiviral nucleoside analogue ganciclovir. Nature. 1992;358(6382):160–2.
23. Cook CH, Yenchar JK, Kraner TO, Davies EA, Ferguson RM. Occult herpes family viruses may increase mortality in critically ill surgical patients. Am J Surg. 1998;176(4):357–60.
24. Heininger A, Jahn G, Engel C, Notheisen T, Unertl K, Hamprecht K. Human cytomegalovirus infections in nonimmunosuppressed critically ill patients. Crit Care Med. 2001;29(3):541–7.
25. Prosch S, Wendt CE, Reinke P, Priemer C, Oppert M, Kruger DH, et al. A novel link between stress and human cytomegalovirus (HCMV) infection: sympathetic hyperactivity stimulates HCMV activation. Virology. 2000;272(2):357–65.
26. Chiche L, Forel JM, Roch A, Guervilly C, Pauly V, Allardet-Servent J, et al. Active cytomegalovirus infection is common in mechanically ventilated medical intensive care unit patients. Crit Care Med. 2009;37(6):1850–7.
27. Cook CH, Martin LC, Yenchar JK, Lahm MC, McGuinness B, Davies EA, et al. Occult herpes family viral infections are endemic in critically ill surgical patients. Crit Care Med. 2003;31(7):1923–9.
28. Jaber S, Chanques G, Borry J, Souche B, Verdier R, Perrigault PF, et al. Cytomegalovirus infection in critically ill patients: associated factors and consequences. Chest. 2005;127(1):233–41.
29. Kutza AS, Muhl E, Hackstein H, Kirchner H, Bein G. High incidence of active cytomegalovirus infection among septic patients. Clin Infect Dis. 1998;26(5):1076–82.
30. von Muller L, Klemm A, Weiss M, Schneider M, Suger-Wiedeck H, Durmus N, et al. Active cytomegalovirus infection in patients with septic shock. Emerg Infect Dis. 2006;12(10):1517–22.
31. Domart Y, Trouillet JL, Fagon JY, Chastre J, Brun-Vezinet F, Gibert C. Incidence and morbidity of cytomegaloviral infection in patients with mediastinitis following cardiac surgery. Chest. 1990;97(1):18–22.
32. Soderberg-Naucler C, Fish KN, Nelson JA. Reactivation of latent human cytomegalovirus by allogeneic stimulation of blood cells from healthy donors. Cell. 1997;91(1):119–26.
33. Bowden RA, Sayers M, Flournoy N, Newton B, Banaji M, Thomas ED, et al. Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation. N Engl J Med. 1986;314(16):1006–10.
34. Kalil AC, Florescu DF. Prevalence and mortality associated with cytomegalovirus infection in nonimmunosuppressed patients in the intensive care unit. Crit Care Med. 2009;37(8):2350–8.
35. Rafailidis PI, Mourtzoukou EG, Varbobitis IC, Falagas ME. Severe cytomegalovirus infection in apparently immunocompetent patients: a systematic review. Virol J. 2008;5:47.
36. Papazian L, Doddoli C, Chetaille B, Gernez Y, Thirion X, Roch A, et al. A contributive result of open-lung biopsy improves survival in acute respiratory distress syndrome patients. Crit Care Med. 2007;35(3):755–62.
37. Coisel Y, Bousbia S, Forel JM, Hraiech S, Lascola B, Roch A, et al. Cytomegalovirus and herpes simplex virus effect on the prognosis of mechanically ventilated patients suspected to have ventilator-associated pneumonia. PLoS One. 2012;7(12):e51340.
38. Heininger A, Haeberle H, Fischer I, Beck R, Riessen R, Rohde F, et al. Cytomegalovirus reactivation and associated outcome of critically ill patients with severe sepsis. Crit Care. 2011;15(2):R77.
39. Papazian L, Fraisse A, Garbe L, Zandotti C, Thomas P, Saux P, et al. Cytomegalovirus. An unexpected cause of ventilator-associated pneumonia. Anesthesiology. 1996;84(2):280–7.
40. Ong DS, Spitoni C, Klein Klouwenberg PM, Verduyn Lunel FM, Frencken JF, Schultz MJ, et al. Cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome. Intensive Care Med. 2016;42(3):333–41.
41. Papazian L, Hraiech S, Lehingue S, Roch A, Chiche L, Wiramus S, et al. Cytomegalovirus reactivation in ICU patients. Intensive Care Med. 2016;42(1):28–37.
42. Chou S. Newer methods for diagnosis of cytomegalovirus infection. Rev Infect Dis. 1990;12(Suppl. 7):S727–36.
43. Lisboa LF, Asberg A, Kumar D, Pang X, Hartmann A, Preiksaitis JK, et al. The clinical utility of whole blood versus plasma cytomegalovirus viral load assays for monitoring therapeutic response. Transplantation. 2011;91(2):231–6.
44. Kalil AC, Levitsky J, Lyden E, Stoner J, Freifeld AG. Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med. 2005;143(12):870–80.
45. Chanques G, Jaber S. Treating HSV and CMV reactivations in critically ill patients who are not immunocompromised: con. Intensive Care Med. 2014;40(12):1950–3.
46. Eddleston M, Peacock S, Juniper M, Warrell DA. Severe cytomegalovirus infection in immunocompetent patients. Clin Infect Dis. 1997;24(1):52–6.
47. Kalil AC, Florescu DF. Is cytomegalovirus reactivation increasing the mortality of patients with severe sepsis? Crit Care. 2011;15(2):138.
48. Forel JM, Martin-Loeches I, Luyt CE. Treating HSV and CMV reactivations in critically ill patients who are not immunocompromised: pro. Intensive Care Med. 2014;40(12):1945–9.
49. Florescu DF, Kalil AC. Cytomegalovirus infections in non-immunocompromised and immunocompromised patients in the intensive care unit. Infect Disord Drug Targets. 2011;11(4):354–64.
50. Docke WD, Prosch S, Fietze E, Kimel V, Zuckermann H, Klug C, et al. Cytomegalovirus reactivation and tumour necrosis factor. Lancet. 1994;343(8892):268–9.
51. Stephan F, Meharzi D, Ricci S, Fajac A, Clergue F, Bernaudin JF. Evaluation by polymerase chain reaction of cytomegalovirus reactivation in intensive care patients under mechanical ventilation. Intensive Care Med. 1996;22(11):1244–9.
52. Razonable RR, Fanning C, Brown RA, Espy MJ, Rivero A, Wilson J, et al. Selective reactivation of human herpesvirus 6 variant A occurs in critically ill immunocompetent hosts. J Infect Dis. 2002;185(1):110–3.
53. von Muller L, Klemm A, Durmus N, Weiss M, Suger-Wiedeck H, Schneider M, et al. Cellular immunity and active human cytomegalovirus infection in patients with septic shock. J Infect Dis. 2007;196(9):1288–95.
54. Chilet M, Aguilar G, Benet I, Belda J, Tormo N, Carbonell JA, et al. Virological and immunological features of active cytomegalovirus infection in nonimmunosuppressed patients in a surgical and trauma intensive care unit. J Med Virol. 2010;82(8):1384–91.
55. Smith CA, Conroy LT, Pollock M, Ruddy J, Binning A, McCruden EA. Detection of herpes viruses in respiratory secretions of patients undergoing artificial ventilation. J Med Virol. 2010;82(8):1406–9.
56. Bordes J, Maslin J, Prunet B, d’Aranda E, Lacroix G, Goutorbe P, et al. Cytomegalovirus infection in severe burn patients monitoring by real-time polymerase chain reaction: a prospective study. Burns. 2011;37(3):434–9.
57. De Vlieger G, Meersseman W, Lagrou K, Wouters P, Wilmer A, Peetermans WE, et al. Cytomegalovirus serostatus and outcome in nonimmunocompromised critically ill patients. Crit Care Med. 2012;40(1):36–42.
58. Ishioka H, Sanui M, Tsutsumi Y, Yanase F, Shiotsuka J. Low prevalence of active cytomegalovirus infection in a cardiovascular intensive care unit. J Intensive Care. 2014;2(1):12.
59. Walton AH, Muenzer JT, Rasche D, Boomer JS, Sato B, Brownstein BH, et al. Reactivation of multiple viruses in patients with sepsis. PLoS One. 2014;9(2):e98819.
60. Ong DS, Klein Klouwenberg PM, Verduyn Lunel FM, Spitoni C, Frencken JF, Dekker HA, et al. Cytomegalovirus seroprevalence as a risk factor for poor outcome in acute respiratory distress syndrome. Crit Care Med. 2015;43(2):394–400.